Anti-LYPD3 Antibody

Price:
Size:
Number:

Anti-LYPD3 Antibody (Rabbit Polyclonal antibody) General Information

Product name
Anti-LYPD3 Antibody
Validated applications
ELISA
Species reactivity
Reacts with: Mouse
Specificity
Mouse LYPD3
Immunogen
Recombinant Mouse C4.4A / LYPD3 protein (Catalog#50546-M08H)
Preparation
Produced in rabbits immunized with purified, recombinant Mouse C4.4A / LYPD3 (rM C4.4A / LYPD3; Catalog#50546-M08H; NP_598504.1; Met 1-His 287). Total IgG was purified by Protein A affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-LYPD3 Antibody (Rabbit Polyclonal antibody) Validated Applications

Application Dilution
ELISA 1:1000-1:2000
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-LYPD3 Antibody: Alternative Names

Anti-2310061G07Rik Antibody; Anti-C4.4a Antibody

LYPD3 Background Information

Ly6 / PLAUR domain-containing protein 3, also known as GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein, MIG-C4 and LYPD3, is a cell membrane protein which contains twoUPAR/Ly6 domains. Human LYPD3 contains twoUPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. It is found in suprabasal keratinocytes of chronic wounds. Weak expression of LYPD3 is found in esophagus and peripheral blood mononuclear cells. It is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression of LYPD3 is found in the tumor component of some noninvasive superficial lesions and in invasive and metastatic urothelial cancers. LYPD3 is up-regulated in migrating keratinocytes during epithelisation of incisional skin wounds. LYPD3 supports cell migration. It may be involved in urothelial cell-matrix interactions. It may also be involved in tumor progression
Full Name
LY6/PLAUR domain containing 3
Research Areas
References
  • Smith B.A., et al., 2001, Cancer Res. 61:1678-85.
  • Wuerfel J., et al., 2001, Gene 262:35-41.
  • Clark H.F., et al., 2003, Genome Res. 13:2265-70.
  • Fletcher G.C., et al., 2003, Br. J. Cancer 88:579-85.
  • Hansen L.V., et al., 2004, Biochem. Eng. J. 380:845-57.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait